138 related articles for article (PubMed ID: 37656802)
1. Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study.
Svingel LS; Christensen SF; Kjærsgaard A; Stenling A; Paulsson B; Andersen CL; Christiansen CF; Stentoft J; Starklint J; Severinsen MT; Borg Clausen M; Hagemann Hilsøe M; Hasselbalch HC; Frederiksen H; Bak M; Mikkelsen EM
Acta Oncol; 2023 Oct; 62(10):1286-1294. PubMed ID: 37656802
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.
Christensen SF; Svingel LS; Kjaersgaard A; Stenling A; Darvalics B; Paulsson B; Andersen CL; Christiansen CF; Stentoft J; Starklint J; Severinsen MT; Clausen MB; Hilsøe MH; Hasselbalch HC; Frederiksen H; Mikkelsen EM; Bak M
Eur J Haematol; 2022 Nov; 109(5):526-541. PubMed ID: 35900040
[TBL] [Abstract][Full Text] [Related]
3. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
4. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
6. Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study.
Bak M; Jess T; Flachs EM; Zwisler AD; Juel K; Frederiksen H
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32967227
[TBL] [Abstract][Full Text] [Related]
7. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
8. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
9. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
10. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
11. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
12. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
Hur JY; Choi N; Choi JH; Kim J; Won YW
Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
[TBL] [Abstract][Full Text] [Related]
13. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
14. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada.
Heppner J; Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F
BMC Res Notes; 2019 May; 12(1):286. PubMed ID: 31126326
[TBL] [Abstract][Full Text] [Related]
15. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
Hultcrantz M; Ravn Landtblom A; Andréasson B; Samuelsson J; Dickman PW; Kristinsson SY; Björkholm M; Andersson TM
J Intern Med; 2020 Apr; 287(4):448-454. PubMed ID: 31927786
[TBL] [Abstract][Full Text] [Related]
16. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.
Pedersen KM; Bak M; Sørensen AL; Zwisler AD; Ellervik C; Larsen MK; Hasselbalch HC; Tolstrup JS
Cancer Med; 2018 Nov; 7(11):5796-5802. PubMed ID: 30318865
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Dec; 149(12):1687-1693. PubMed ID: 35735335
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Nov; 149(11):1532-1538. PubMed ID: 35735314
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Larsen MK; Skov V; Kjær L; Eickhardt-Dalbøge CS; Knudsen TA; Kristiansen MH; Sørensen AL; Wienecke T; Andersen M; Ottesen JT; Gudmand-Høyer J; Snyder JA; Andersen MP; Torp-Pedersen C; Poulsen HE; Stiehl T; Hasselbalch HC; Ellervik C
Blood Cancer J; 2024 Feb; 14(1):28. PubMed ID: 38331919
[TBL] [Abstract][Full Text] [Related]
20. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]